WO2019016705A1 - Pelicula para aplicação tópica no tratamento de lesões da pele e método para sua obtenção e aplicação - Google Patents
Pelicula para aplicação tópica no tratamento de lesões da pele e método para sua obtenção e aplicação Download PDFInfo
- Publication number
- WO2019016705A1 WO2019016705A1 PCT/IB2018/055304 IB2018055304W WO2019016705A1 WO 2019016705 A1 WO2019016705 A1 WO 2019016705A1 IB 2018055304 W IB2018055304 W IB 2018055304W WO 2019016705 A1 WO2019016705 A1 WO 2019016705A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chitosan
- film
- final concentration
- topical application
- mixture
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims description 16
- 206010040882 skin lesion Diseases 0.000 title claims description 6
- 231100000444 skin lesion Toxicity 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000341 volatile oil Substances 0.000 claims abstract description 17
- 229920001661 Chitosan Polymers 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 29
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- 229940069521 aloe extract Drugs 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 230000006196 deacetylation Effects 0.000 claims description 8
- 238000003381 deacetylation reaction Methods 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 229960004365 benzoic acid Drugs 0.000 claims description 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
- 229960004217 benzyl alcohol Drugs 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 229960003885 sodium benzoate Drugs 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000000527 sonication Methods 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 29
- 206010052428 Wound Diseases 0.000 abstract description 27
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 18
- 230000003078 antioxidant effect Effects 0.000 abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 15
- 239000003963 antioxidant agent Substances 0.000 abstract description 8
- 239000000419 plant extract Substances 0.000 abstract description 6
- 239000012867 bioactive agent Substances 0.000 abstract description 5
- 230000001172 regenerating effect Effects 0.000 abstract description 5
- 206010033372 Pain and discomfort Diseases 0.000 abstract description 3
- 230000000843 anti-fungal effect Effects 0.000 abstract description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 abstract description 2
- 229940121375 antifungal agent Drugs 0.000 abstract description 2
- 230000002358 autolytic effect Effects 0.000 abstract description 2
- 238000001804 debridement Methods 0.000 abstract description 2
- 238000004806 packaging method and process Methods 0.000 abstract 2
- 239000003708 ampul Substances 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 description 27
- 239000011248 coating agent Substances 0.000 description 21
- 238000000576 coating method Methods 0.000 description 21
- 230000008569 process Effects 0.000 description 17
- 235000011399 aloe vera Nutrition 0.000 description 11
- 241001116389 Aloe Species 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000007306 functionalization reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000036560 skin regeneration Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- HDXQYLJUKLAYMH-UHFFFAOYSA-M silver;1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate Chemical compound [Ag+].C1=C2N(CC)C=C(C([O-])=O)C(=O)C2=CC(F)=C1N1CCNCC1 HDXQYLJUKLAYMH-UHFFFAOYSA-M 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001529749 Lavandula Species 0.000 description 1
- 235000002997 Lavandula Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- -1 silver modified montmorillonite Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
Definitions
- the present application discloses a film for topical application in the treatment of skin lesions and their method of production.
- the skin is the largest organ in the human body, and provides protection against dehydration, toxins and microorganisms in the external environment. Skin integrity can be compromised due to different types of injuries, including acute wounds (caused by cuts or burns), chronic wounds (pressure or diabetic ulcers), genetic disorders, and surgical interventions. It is estimated that the prevalence of wounds resulting from surgeries affects about 115 million people. On the other hand, an estimated 40 million people are suffering from chronic wounds. Cutaneous lesions are usually associated with several types of complications, such as infections, electrolyte disturbances, and respiratory failure. In addition, the individual may still suffer emotional and psychological disturbances that may occur due to the long periods of hospitalization and the aesthetic aspect of the scars.
- biomaterials hydrogels, membranes, films, etc.
- materials that have been developed for the treatment of wounds should keep the wound moist, since a dry wound promotes the formation of a crust which prevents cell migration.
- the materials must have the ability to absorb the exudate, as its accumulation at the wound site can lead to maceration of the tissue.
- US2016235881 (A1) discloses a method of preparing a hydrogel having non-adherent properties and without interfering with the bioactivity of the agents contained in said structure for application in the regeneration of lesions.
- the present invention is distinguished from this in that it is biodegradable and in this way it is not necessary to remove the product after treatment of the wound. This property of the film allows reducing the pain felt by the patient during the wound treatment process.
- the production of the product described in US2016235881 (A1) requires the use of oxygen plasma, whereas the product described herein does not require complex techniques for its production.
- Document RU2545735 discloses a hydrogel-based lesion coating containing antimicrobial and antioxidant ingredients: such as silver modified montmorillonite and fulerenol, in order to improve the regeneration process and prevent / reduce infections.
- the present invention is distinguished from this in that it has a naturally occurring coating produced by a simple mechanism, without requiring lengthy purification and purification steps.
- the antimicrobial and antioxidant character of the film is achieved by the incorporation of agents of natural origin (essential oils, plant extracts, and the like) not using silver or synthetic compounds.
- Document KR101429455 (BI) relates to a hydrogel dressing with antioxidant properties for wound treatment using the self-assembly of chitosan as well as its method of production. More specifically, a wound dressing comprising a mixture of polymeric hydrogel and chitosan employing an enzymatic / chemical technique to transform water-insoluble chitosan into low molecular weight molecules.
- the present invention stands out from this, in that it has a film of natural origin produced through a simple mechanism, without resorting to the action of enzymes. Moreover, the present invention has antimicrobial properties.
- CN103446618 comprises a hydrogel having antibacterial activity and its method of preparation.
- the hydrogel consists of 0.1-5% silver norfloxacin, 5-30% polymer, 0-10% plasticizer and water. This hydrogel allows the absorption of the exudates and the prevention of infections.
- the present invention is distinguished from this in that it is essentially composed of biomaterials of natural origin.
- the antibacterial effect of the product proposed here mainly from the native properties of natural products, and not from the addition of agents such as silver norfloxacin.
- Document CN102698312 discloses a hydrogel composed of 1.5-2% chitosan, 45-50% aloe and ⁇ 4% ⁇ -glycerolphosphate to be applied in the wound healing process.
- the present invention is distinguished from this in that the chitosan used in the production of the coating is subjected to processes of functionalization (deacetylation and / or chemical modification with amino acids) in order to enhance the intrinsic properties of the polymer.
- the film has other bioactive agents (components with anti-inflammatory and antioxidant activity), in order to improve the process of skin regeneration.
- This film based on natural polymers allows the formation of a film on the surface of the lesion, which provides protection of the wound against infectious agents, also ensuring an environment conducive to cell proliferation.
- CN101278896 (B) describes the production of a chitosan gel containing silver nanoparticles used for the treatment of the inflammatory and infectious process associated with cutaneous lesions.
- the present invention departs from this, since it does not resort to the use of silver nanoparticles to impart antibacterial properties to the coating.
- the process of functionalization of chitosan with different amino acids allows to potentiate the antibacterial properties of the coating.
- CN104288173 (A) describes a biological coating based on an antibacterial chitosan gel.
- the gel is composed of chitosan and medicinal gelatin.
- the present invention differs in that the modification of chitosan amplifies its antibacterial properties and can act at the level of various bacterial strains, including multiresistant strains. Additionally, the incorporation of aloe vera imparts moisturizing, anti-inflammatory and regenerative properties to the coating.
- CN103110976 discloses the recipe of an antibacterial gel and its method of preparation, wherein the main component is the chitosan-iodine complex in order to provide disinfectant properties to the gel.
- the present invention is distinguished from this in that the proposed film exhibits antibacterial properties which, in addition to inducing the death of the microorganisms, also prevents the growth thereof, throughout the wound healing process.
- This coating also has very important properties in the healing process, namely anti-inflammatory and antioxidant character.
- WO 2003068281 discloses a chitosan hydrogel having a degree of deacetylation of greater than 40%.
- the present invention stands out from this, insofar as the proposed film presents besides chitosan with high degree of deacetylation, the functionalization with biomolecules which potentiates the antibacterial and antifungal activity of chitosan.
- the incorporation of plant extracts and other bioactive molecules in the film composition contributes to improve the performance of the gel in the process of wound healing.
- CA2712527 (C) reports a pharmaceutical composition designated to function with a skin protective film composed of chitosan and agents which impart curative, soothing and moisturizing properties.
- the film is composed of chitosan and aloe which confers hydration capacity and also consists of bioactive molecules that enhance the antibacterial, anti-inflammatory and antioxidant properties of the coating, which also are central to the treatment of skin lesions.
- CN101502667 discloses a transparent hydrogel composed of chitosan, polyacrylic acid and polyvinylpyrrolidone having hemostatic properties, high water absorption and good applicability.
- the present invention stands out from this, in that the coating has good water-absorbing capacity, antibacterial, anti-inflammatory and antioxidant properties without the use of synthetic polymers.
- the work entitled "Thermoresponsive chitosan-agarose hydrogel for skin regeneration” (Miguel et al., 2014) describes a biocompatible and antibacterial thermoresponsive hydrogel capable of promoting wound healing.
- the present invention departs from this system, since the chitosan used in the coating production is functionalized with bioactive molecules and, in this way, the antibacterial and healing properties are increased. It is expected that this system promotes a faster healing process.
- the present invention has anti-inflammatory and antioxidant properties.
- the work entitled “Chitosan / arginine-chitosan polymer blends for the assembly of nanofibrous membranes for wound regeneration” reports the production of a dressing composed of chitosan based on nanofibers using the technique of electrofying.
- the present invention stands out from this, in that the coating disclosed herein is in the form of a film, which has the ability to provide a moist environment at the lesion site, which is favorable to the skin regeneration process.
- the inclusion of aloe extracts, essential oils and other biomolecules provides anti-inflammatory and antioxidant properties to the film.
- the work titled “Electrospun Polycaprolactone / Aloe Vera_ Chitosan Nanofibrous Asymmetric Membranes Aimed for Wound Healing Applications” (Miguel et al., 2017) describes a membrane produced through the electro-spinning process.
- the present invention differs from this in that the coating is a film having an enormous hydration capacity as well as the absorption of the exudates.
- chitosan is functionalized with biomolecules, which amplifies the intrinsic properties of the polymer.
- the work titled "Acceleration of wound contraction and healing with a photocrosslinkable chitosan hydrogel” reports a photoreticable hydrogel of chitosan.
- the present invention stands out in that the coating is composed of chitosan functionalized with amino acids extracts of aloe which allows to give the film good moisturizing properties as well as antibacterial, anti-inflammatory and antioxidant properties. Furthermore, the present invention does not require complicated or time-consuming processes for cross-linking to occur. The addition of thickening components enables simple application of the protective film.
- the present invention differs in that the formulation process adopted in the production of the film is quite simple and does not require the use of time consuming, chemical processes.
- the film has antimicrobial, anti-inflammatory, antioxidant and regenerative properties mediated by its constituents.
- the present application discloses a film for topical application in the treatment of skin lesions and their method of production.
- the deacetylated chitosan has a degree of deacetylation between 55% and 99.99%.
- the essential oils are soybean oil, lavender oil or a combination thereof.
- the thickening agent is ethylene glycol, mannitol, xylitol, butyl tetraol or a combination thereof.
- the preservative is benzoic acid, sodium benzoate, calcium gluconate, methylparaben, sorbic acid, benzyl alcohol or a combination thereof.
- the film for topical application is used in the treatment of skin lesions.
- the present application is based on the development of a hydrogel based film based on natural components for coating wounds.
- This film has the ability to impart a humid environment to the wound so that natural autolytic debridement occurs.
- the film will also incorporate bioactive agents (eg acetylsalicylic acid, essential oils, plant extracts and others) that confer antibacterial, antifungal, anti-inflammatory, antioxidant and regenerative properties.
- bioactive agents eg acetylsalicylic acid, essential oils, plant extracts and others
- the different application strategies eg through individual packs, ampoules or syringes are also explored in order to simplify the patients' lives, and to minimize the pain and discomfort felt by them, when the treatment is carried out at the level of the patients. primary care.
- the preferred form of application of the film of the present application is through a gel-administered formulation at the wound site so as to facilitate topical application and protect the lesion site from external agents.
- This formulation stands out from those on the market because it has a qualitative constitution based on natural and / or modified products, including mixtures of bioactive agents.
- the gel will have in its constitution chitosan, plant extracts and / or mixture of extracts of plants that may belong to the genus of Aloe, Matricaria, Lavandula L., among others, and / or antibacterial agents and other active substances.
- the film is defined as the film defined according to the embodiments described herein, in its solid, liquid or gel form.
- the present application relates to the development of a hydrogel film based on natural components for coating wounds, obtained in accordance with the following steps:
- Chitosan with a molecular weight of 1 to 375 KDa (500 mg) is dissolved in 10 ml of sodium hydroxide (1M) for 3-4 hours at 50 ° C. Subsequently, the solution is extensively rinsed with miliq water, and the pH of the solution is adjusted to 7. Chitosan with a degree of deacetylation of 55 to 99.999%, used thereafter. a high degree of deacetylation of chitosan allows increasing the amount of positively charged groups on the chitosan surface, thus improving its biological properties, namely bioadhesive, antimicrobial properties and the hydrophilicity of the material.
- the previously deacetylated chitosan is functionalized with arginine.
- L-arginine is coupled to the chitosan polymer chain through the amidation reaction of the primary amine groups present in the chitosan glucosamine units, using the chemical reaction of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC) / N- hydroxysuccinimide (NHS).
- EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
- NHS N- hydroxysuccinimide
- aloe extract A plant of the genus of aloe with age comprised between 6-10 years is selected. After washing with distilled water it is sterilized under ultraviolet radiation for about 30-45 minutes. Subsequently, the leaves of the plant are separated from the plant extract with the aid of a scalpel. The extract of the plant is homogenized using an ultra homogenizer, for 15-25 minutes. Subsequently, a centrifugation is performed in order to purify the aloe extract.
- Aloe is a polysaccharide composed essentially of mannose (60.73%), galactose (16.42%) and glucose (9.16%).
- the aloe extract has excellent anti-inflammatory, antiseptic and analgesic properties.
- the preservatives (benzoic acid, sodium benzoate, calcium gluconate, methylparaben, sorbic acid, benzyl alcohol) are added in a proportion which may range from 0.05% - 0.10%; the thickening agents (ethylene glycol, mannitol, xylitol, butyl tetraol, among others) are also incorporated into the blend in order to ensure gel flowability in a range of from 0.05% -0.20%.
- Essential oils and / or a mixture of essential oils such as soybean oil, lavender oil, and / or other flavoring agents are added at a final concentration which may range from 0-5%
- the preparation of the film comprises the following steps: Dissolve a mixture of deacetylated chitosan (at a percentage of 15% and 60%) and chitosan modified (at a percentage of 15% and 60%) with amino acids in 100 ml of a dilute lactic acid solution at a percentage of 0.5 % to 1% (w / v);
- the gel is ready to be applied to the injured area.
- the film is formed after application to the injured area.
- the essential oil is soybean oil, lavender oil or a combination thereof.
- the thickening agent is ethylene glycol, mannitol, xylitol, butyl tetraol or a combination thereof.
- the preservative is benzoic acid, sodium benzoate, calcium gluconate, methylparaben, sorbic acid, benzyl alcohol or a combination thereof.
- the pH is adjusted using a solution of sodium hydroxide or a solution of organic acid.
- the topical application film of the present technology comprises the following elements:
- the technology described in the present application is intended for the treatment or amelioration of dermatological symptoms, due to different types of lesions, which include acute wounds (caused by cuts or burns), chronic wounds (pressure or diabetic ulcers), genetic disorders and surgical interventions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880042926.3A CN110869062A (zh) | 2017-07-19 | 2018-07-17 | 用于在皮肤损伤的处理中局部应用的薄膜及其获得和应用方法 |
JP2019569732A JP2020528404A (ja) | 2017-07-19 | 2018-07-17 | 皮膚病変の治療における局所適用のためのフィルム、およびそれを得る方法ならびに適用方法 |
EP18765718.4A EP3656404A1 (en) | 2017-07-19 | 2018-07-17 | Film for topical use for treating skin lesions and method for producing and applying same |
CA3066321A CA3066321A1 (en) | 2017-07-19 | 2018-07-17 | Film for topical application in the treatment of skin lesions and method of obtaining and applying it |
US16/619,842 US11058712B2 (en) | 2017-07-19 | 2018-07-17 | Film for topical application in the treatment of skin lesions and method of obtaining and applying same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT110208 | 2017-07-19 | ||
PT11020817 | 2017-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019016705A1 true WO2019016705A1 (pt) | 2019-01-24 |
Family
ID=63517933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/055304 WO2019016705A1 (pt) | 2017-07-19 | 2018-07-17 | Pelicula para aplicação tópica no tratamento de lesões da pele e método para sua obtenção e aplicação |
Country Status (6)
Country | Link |
---|---|
US (1) | US11058712B2 (pt) |
EP (1) | EP3656404A1 (pt) |
JP (1) | JP2020528404A (pt) |
CN (1) | CN110869062A (pt) |
CA (1) | CA3066321A1 (pt) |
WO (1) | WO2019016705A1 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2594756A (en) * | 2020-02-28 | 2021-11-10 | Aga Nanotech Ltd | An activatable wound dressing |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112940286B (zh) * | 2021-02-01 | 2022-09-09 | 北京科技大学 | 一种自愈合、优异弹性回复与抗菌水凝胶敷料的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030091507A (ko) * | 2002-05-28 | 2003-12-03 | 주식회사 제닉 | 키토산-아세틸살리실산(아스피린) 염 화합물 제조방법 및이로부터 제조된 키토산-아세틸살리실산 염 화합물 |
WO2011004399A2 (en) * | 2009-07-09 | 2011-01-13 | Manoj Vinoy Mojamdar | Liquid filmogenic chitosan skin for wound healing and a method for preparation thereof |
US20160060362A1 (en) * | 2006-06-02 | 2016-03-03 | Shenda Baker | Chitosan-derivative compounds and methods of controlling microbial populations |
CN106421886A (zh) * | 2016-08-17 | 2017-02-22 | 倪娟形 | 一种创面修复水凝胶敷料及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1179352A1 (en) * | 2000-08-08 | 2002-02-13 | MONTERESEARCH S.r.l. | Topical composition for covering a skin lesion |
FR2836044A1 (fr) | 2002-02-15 | 2003-08-22 | Octaris | Composition pour la reparation et la cicatrisation cutanee comprenant exclusivement un vrai hydrogel physique de chitosane |
US20050191270A1 (en) * | 2004-02-27 | 2005-09-01 | Hydromer, Inc. | Anti-infectious hydrogel compositions |
KR100676937B1 (ko) * | 2005-06-01 | 2007-02-02 | 주식회사 제닉 | 피부미용 및 상처치료용 수용성 필름 및 그 제조방법 |
CL2008000156A1 (es) | 2008-01-18 | 2008-08-01 | Igloo Zone Chile S A | Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel. |
CN101278896B (zh) | 2008-05-23 | 2012-11-14 | 山东赛克赛斯药业科技有限公司 | 壳聚糖纳米银凝胶剂及其应用 |
CN101502667B (zh) | 2009-03-13 | 2012-12-05 | 东华大学 | 一种医用壳聚糖透明水凝胶创伤敷料及其制备和应用 |
CN102698312B (zh) | 2012-05-24 | 2014-08-06 | 南方医科大学 | 一种皮肤创面修复水凝胶及其制备方法 |
CN103110976A (zh) | 2012-12-20 | 2013-05-22 | 贵州扬生医用器材有限公司 | 一种皮肤抗菌凝胶配方及其制备方法 |
KR101457789B1 (ko) * | 2013-02-13 | 2014-11-03 | 동아제약 주식회사 | 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법 |
KR101429455B1 (ko) | 2013-05-15 | 2014-08-13 | 주식회사 케이티에이치아시아 | 자가합성체 키토산을 이용한 상처치료용 하이드로겔 패치 및 그 제조 방법 |
CN103446618B (zh) | 2013-09-16 | 2015-11-18 | 河南科高辐射化工科技有限公司 | 一种抗菌水凝胶伤口被覆膜及采用该被覆膜制成的创面贴 |
CA2925797A1 (en) | 2013-09-30 | 2015-04-02 | University Of Manitoba | Non-adherent hydrogel coating for wound dressings and methods for making the same |
RU2545735C1 (ru) | 2013-11-06 | 2015-04-10 | Кирилл Николаевич Касанов | Биоактивное гидрогелевое раневое покрытие |
CN104288173A (zh) | 2014-07-14 | 2015-01-21 | 湖北博康医药科技有限公司 | 一种壳聚糖抗菌凝胶生物敷料 |
CN105412980B (zh) * | 2015-12-28 | 2018-09-28 | 任新界 | 一种门诊小手术切口用医疗胶以及制备方法 |
CN105709272A (zh) * | 2016-03-25 | 2016-06-29 | 华东理工大学 | 一种用于创面治疗的新型生物抗菌敷料 |
CN106039394A (zh) * | 2016-06-02 | 2016-10-26 | 四川奎星医用高分子制品有限责任公司 | 含有抗菌药物的医用复合壳聚糖凝胶 |
-
2018
- 2018-07-17 CA CA3066321A patent/CA3066321A1/en not_active Abandoned
- 2018-07-17 JP JP2019569732A patent/JP2020528404A/ja active Pending
- 2018-07-17 WO PCT/IB2018/055304 patent/WO2019016705A1/pt unknown
- 2018-07-17 US US16/619,842 patent/US11058712B2/en active Active
- 2018-07-17 EP EP18765718.4A patent/EP3656404A1/en not_active Withdrawn
- 2018-07-17 CN CN201880042926.3A patent/CN110869062A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030091507A (ko) * | 2002-05-28 | 2003-12-03 | 주식회사 제닉 | 키토산-아세틸살리실산(아스피린) 염 화합물 제조방법 및이로부터 제조된 키토산-아세틸살리실산 염 화합물 |
US20160060362A1 (en) * | 2006-06-02 | 2016-03-03 | Shenda Baker | Chitosan-derivative compounds and methods of controlling microbial populations |
WO2011004399A2 (en) * | 2009-07-09 | 2011-01-13 | Manoj Vinoy Mojamdar | Liquid filmogenic chitosan skin for wound healing and a method for preparation thereof |
CN106421886A (zh) * | 2016-08-17 | 2017-02-22 | 倪娟形 | 一种创面修复水凝胶敷料及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2594756A (en) * | 2020-02-28 | 2021-11-10 | Aga Nanotech Ltd | An activatable wound dressing |
GB2592911B (en) * | 2020-02-28 | 2023-06-28 | Aga Nanotech Ltd | A plasma-activatable wound dressing for treatment of infections |
GB2594756B (en) * | 2020-02-28 | 2024-05-01 | Aga Nanotech Ltd | An activatable wound dressing |
Also Published As
Publication number | Publication date |
---|---|
JP2020528404A (ja) | 2020-09-24 |
EP3656404A1 (en) | 2020-05-27 |
US11058712B2 (en) | 2021-07-13 |
CN110869062A (zh) | 2020-03-06 |
CA3066321A1 (en) | 2019-01-24 |
US20200138851A1 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Varaprasad et al. | Alginate-based composite materials for wound dressing application: A mini review | |
Yuan et al. | Nano-silver functionalized polysaccharides as a platform for wound dressings: A review | |
Wang et al. | Hydrogel sheets of chitosan, honey and gelatin as burn wound dressings | |
ES2361459B1 (es) | Gel de quitosano para aplicaciones dermatológicas, proceso de obtención y uso del mismo. | |
JP6069394B2 (ja) | 医薬組成物 | |
CN106822988B (zh) | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 | |
Moholkar et al. | Recent advances in biopolymer-based formulations for wound healing applications | |
CN105012993A (zh) | 一种阳离子医用生物胶抗菌敷料及其制备方法 | |
Singh et al. | Application of tragacanth gum and alginate in hydrogel wound dressing's formation using gamma radiation | |
CN109646712B (zh) | 一种胶态硫液体敷料及其制备方法 | |
CN111068103B (zh) | 一种手术伤口用长效抑菌凝胶敷料及其制备方法 | |
Zahra et al. | Exploring the recent developments of alginate silk fibroin material for hydrogel wound dressing: a review | |
US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
Priya et al. | Exploring polysaccharide-based bio-adhesive topical film as a potential platform for wound dressing application: A review | |
RU2699362C2 (ru) | Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран | |
CN112587655B (zh) | 一种用于烧伤的木立芦荟-壳聚糖-氧化石墨烯凝胶冻干粉 | |
Xu et al. | Engineering a naturally-derived wound dressing based on bio-ionic liquid conjugation | |
CN107595819B (zh) | 一种纳米金刚石改性液体创可贴及其制备方法 | |
Anisa et al. | Modification of Nanocellulose as Conjugate of infection-causing Antibacterial Hydrogel | |
Zubair et al. | Emerging trends and challenges in polysaccharide derived materials for wound care applications: A review | |
Nqoro et al. | Alginate-based wound dressings for skin healing and regeneration | |
Alibolandi et al. | Biopolymer-Based Hydrogel Wound Dressing | |
Rajwade et al. | Wound Treatment Using Nanomaterials | |
Abbasinia et al. | Nanocomposite sponge based on sodium alginate, polyvinyl alcohol, carbon dots, and woolly hedge nettle antibacterial extract for wound healing | |
Fletes-Vargas et al. | Natural Hydrogels as Wound Dressing for Skin Wound-Healing Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18765718 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3066321 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019569732 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018765718 Country of ref document: EP Effective date: 20200219 |